Ad­vo­cates, ex­perts cry foul over Amy­lyx's new ALS drug, cit­ing is­sues with price, PhI­II com­mit­ment

Not 24 hours af­ter earn­ing the first ALS drug ap­proval in five years, Amy­lyx Phar­ma­ceu­ti­cals’ Re­lyvrio is al­ready draw­ing scruti­ny. And it’s com­ing from mul­ti­ple fronts.

In an in­vestor call Fri­day morn­ing, Amy­lyx re­vealed that it would charge about $158,000 per year, a price point that im­me­di­ate­ly drew back­lash from ALS ad­vo­cates and some out­side ob­servers. The cost re­veal had been high­ly an­tic­i­pat­ed in the im­me­di­ate hours af­ter Thurs­day evening’s ap­proval, though Amy­lyx on­ly teased Re­lyvrio would cost less than pre­vi­ous­ly ap­proved drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER